Hydroxyethyl starch 6%, 130/0.4 vs. a balanced crystalloid solution in cardiopulmonary bypass priming: A randomized, prospective study

Journal of Cardiothoracic Surgery

Volumn 8, Issue 1, 2013, Pages

  Gurbuz, Hasan Alper ^a,b   Durukan, Ahmet Baris ^a,b   Salman, Nevriye ^a   Tavlasoglu, Murat ^c   Durukan, Elif ^d   Ucar, Halil Ibrahim ^a   Yorgancioglu, Cem ^a  

^a ANKARA NUMUNE HOSPITAL   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c DIYARBAKIR MILITARY HOSPITAL   (Turkey)

^d BASKENT UNIVERSITY   (Turkey)

Author keywords

Coronary artery bypass; Hetastarch; Outcome assessment

Indexed keywords

HETASTARCH DERIVATIVE; ISOTONIC SOLUTION; PLASMA SUBSTITUTE; CRYSTALLOID;

AGED; ARTICLE; CARDIOPULMONARY BYPASS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CRYSTALLOID; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ATRIAL FIBRILLATION; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS; FEMALE; HUMANS; HYDROXYETHYL STARCH DERIVATIVES; ISOTONIC SOLUTIONS; MALE; MIDDLE AGED; PLASMA SUBSTITUTES; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84875820809     PISSN: None     EISSN: 17498090     Source Type: Journal    
DOI: 10.1186/1749-8090-8-71     Document Type: Article

References (19)

1. Bahar I, Akgul A, Ozatik MA, Vural KM, Demirbag AE, Boran M, Tasdemir O. Acute renal failure following open heart surgery: risk factors and prognosis. Perfusion 2005, 20:317-322. 10.1191/0267659105pf829oa, 16363316.
2. Vermeer H, Teerenstra S, de Sevaux RG, van Swieten HA, Weerwind PW. The effect of hemodilution during normothermic cardiac surgery on renal physiology and function: a review. Perfusion 2008, 23:329-338. 10.1177/0267659109105398, 19454561.
3. Atluri P, Kozin ED, Hiesinger W, Woo YJ. Off-pump, minimally invasive and robotic coronary revascularization yield improved outcomes over traditional on-pump CABG. Int J Med Robot 2009, 5:1-12. 10.1002/rcs.230, 19117020.
4. Warren OJ, Smith AJ, Alexiou C, Rogers PL, Jawad N, Vincent C, Darzi AW, Athanasiou T. The inflammatory response to cardiopulmonary bypass: part 1-mechanisms of pathogenesis. J Cardiothorac Vasc Anesth 2009, 23:223-231. 10.1053/j.jvca.2008.08.007, 18930659.
5. Warren OJ, Watret AL, de Wit KL, Alexiou C, Vincent C, Darzi AW, Athanasiou T. The inflammatory response to cardiopulmonary bypass: part 2-anti-inflammatory therapeutic strategies. J Cardiothorac Vasc Anesth 2009, 23:384-393. 10.1053/j.jvca.2008.09.007, 19054695.
6. Choi YS, Shim JK, Hong SW, Kim JC, Kwak YL. Comparing the effects of 5% albumin and 6% hydroxyethyl starch 130/0.4 on coagulation and inflammatory response when used as priming solutions for cardiopulmonary bypass. Minerva Anestesiol 2010, 76:584-591.
7. Liou HL, Shih CC, Chao YF, Lin NT, Lai ST, Wang SH, Chen HI. Inflammatory response to colloids compared to crystalloid priming in cardiac surgery patients with cardiopulmonary bypass. Chin J Physiol 2012, 55:210-218.
8. Kuitunen AH, Hynynen MJ, Vahtera E, Salmenpera MT. Hydroxyethyl starch as a priming solution for cardiopulmonary bypass impairs hemostasis after cardiac surgery. Anesth Analg 2004, 98:291-297.
9. Tiryakioglu O, Yildiz G, Vural H, Goncu T, Ozyazicioglu A, Yavuz S. Hydroxyethyl starch versus Ringer solution in vardiopulmonary bypass prime solutions (a randomized controlled trial). J Cardiothorac Surg 2008, 3:45. 10.1186/1749-8090-3-45, 2483980, 18620591.
10. Yap WW, Young D, Pathi V. Effects of gelatine and medium molecular weight starch as priming fluid in cardiopulmonary bypass- a randomized controlled trial. Perfusion 2007, 22:57-61. 10.1177/0267659107077903, 17633136.
11. Shi XY, Zou Z, He XY, Xu HT, Yuan HB, Liu H. Hydroxyethyl starch for cardiovascular surgery: a systematic review of randomized controlled trials. Eur J Clin Pharmacol 2011, 67:767-782. 10.1007/s00228-011-1008-5, 21365330.
12. Akkucuk FG, Kanbak M, Ayhan B, Celebioglu B, Aypar U. The effect of HES (130/0.4) usage as the priming solution on renal function in children undergoing cardiac surgery. Ren Fail 2013, 35:210-215. 10.3109/0886022X.2012.747139, 23228215.
13. Ertmer C, Wulf H, Van Aken H, Friederich P, Mahl C, Bepperling F, Westphal M, Gogarten W. Efficacy and safety of 10% HES 130/0.4 versus 10% HES 200/0.5 for plasma volume expansion in cardiac surgery patients. Minerva Med 2012, 103:111-122.
14. Alavi SM, Ahmadi BB, Baharestani B, Babaei T. Comparison of the effects of gelatin, Ringer's solution and a modern hydroxyl ethyl starch solution after coronary artery bypass graft surgery. Cardiovasc J Afr 2012, 23:428-431. 10.5830/CVJA-2012-026, 23044498.
15. Maesen B, Nijs J, Maesen J, Allessie M, Schotten U. Post-Operative Atrial Fibrillation: A Maze of Mechanisms. Europace 2012, 14:159-174. 10.1093/europace/eur208, 3262403, 21821851.
16. Guo Y, Lip GY, Apostolakis S. Inflammation in Atrial Fibrillation. J Am Coll Cardiol 2012, 60:2263-2270. 10.1016/j.jacc.2012.04.063, 23194937.
17. Friedrichs K, Klinke A, Baldus S. Inflammatory pathways underlying Atrial Fibrillation. Trends Mol Med 2011, 17:556-563. 10.1016/j.molmed.2011.05.007, 21763201.
18. Tian J, Lin X, Zhou W, Xu J. Hydroxyethyl starch inhibits NF-KappaB activation and prevents the expression of inflammatory mediators in Endotoxic Rats. Ann Clin Lab Sci 2003, 33:451-458.
19. Xie J, Lv R, Yu L, Huang W. Hydroxyethyl Starch 130/0.4 inhibits production of plasma Proinflammatory cytokines and attenuates nuclear factor-KappaB activation and Toll-Like receptors expression in Monocytes during Sepsis. J Surg Res 2010, 160:133-138. 10.1016/j.jss.2009.05.050, 19766237.